Oliger Christy J. 4
4 · Karyopharm Therapeutics Inc. · Filed May 26, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) Director Christy Oliger Receives RSU Award
What Happened Christy J. Oliger, a director of Karyopharm Therapeutics, was awarded 15,508 restricted stock units (RSUs) on May 21, 2026. The RSUs were granted at $0.00 (code A — award/grant), so there was no cash exchanged. The award converts one-for-one into common shares; total reported value at grant is $0 in the filing.
Key Details
- Transaction date: 2026-05-21; Form 4 filed: 2026-05-26 (filed within the standard two-business-day window given the May 25 federal holiday).
- Grant: 15,508 RSUs; price reported: $0.00; transaction code: A (award/grant).
- Shares owned after transaction: Not specified in this filing.
- Footnote: RSUs convert 1:1 to common stock and vest 100% on May 21, 2027. Delivery of the shares is deferred until the earlier of (a) the director’s separation from service or (b) a change-in-control event.
- No 10b5-1 plan, cashless exercise, or tax-withholding sale noted in this filing.
Context This is a standard director equity award (compensation) rather than an open-market purchase or sale. RSU grants compensate and align directors with shareholder interests but do not represent an immediate cash investment or liquidity event. The filing appears timely based on the reported dates and the Memorial Day holiday.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-21+15,508→ 15,508 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.